Number of trials, total sample size and annual global burden of disease for each disease
| No of trials* | No exclusively examining primary disease | Total sample size† | Annual global burden of disease in 1000s of DALYs | |
|---|---|---|---|---|
| Leishmaniasis | 184 | 179 | 23 039 | 2090 |
| Geohelminth infections | 160 | 133 | 46 887 | 3796 |
| Ascariasis | — | 79‡ | — | — |
| Hookworm | — | 77‡ | — | — |
| Trichuriasis | — | 66‡ | — | — |
| Strongyloidiasis | — | 14‡ | — | — |
| Schistosomiasis | 142 | 114 | 35 026 | 1702 |
| Leprosy | 120 | 77 | 14 772 | 198 |
| Lymphatic filariasis | 73 | 73 | 9996 | 5777 |
| Onchocerciasis | 62 | 53 | 25 182 | 484 |
| Trachoma | 54 | 29 | 10 420 | 2329 |
| Rabies§ | 45 | 13 | 6756 | 1780 |
| Cysticercosis | 32 | 32 | 2872 | — |
| Dengue | 24 | 4 | 2374 | 616 |
| American trypanosomiasis | 22 | 8 | 1772 | 667 |
| Echinococcosis | 15 | 15 | 1064 | 666 |
| Foodborne trematode infections | 14 | 14 | 1306 | 665 |
| Fascioliasis | 5‡ | — | — | |
| Opisthorchiasis | 4‡ | — | — | |
| Clonorchiasis | 3‡ | — | — | |
| Paragonimiasis | 2‡ | — | — | |
| Fasciolopsiasis | 1‡ | — | — | |
| Human African trypanosomiasis¶ | 10 | 10 | 2840 | 1525 |
| Dracunculiasis | 9 | 9 | 798 | — |
| Buruli ulcer | 5 | 5 | 337 | — |
*Includes both primary disease and its complications.
†Calculated with “units of randomisation” in each trial, including number of clusters in cluster randomised trials and number of randomised units in trials in which unit of randomisation was not individual (for example, skin lesions in leishmaniasis or eyes in trachoma). It slightly underestimates number of individual participants.
‡Sum of individual categories is greater than total number of trials because of trials that examined more than disease.
§Thirteen trials examined post-exposure prophylaxis after appropriate exposure, 32 others were simulated prophylaxis trials
¶Early and late stage Trypanosoma brucei gambiense.